AstraZeneca PLC closed 19.20% below its 52-week high of £133.88, which the company achieved on September 3rd.

Scientists have developed a new machine learning framework that has shown the potential to be more accurate at inverse ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Demand is rising for AI-powered robots that can clean offices or roll around moving items from one part of a building to ...

AstraZeneca is making a bold move. The drug giant just teamed up with CSPC in a deal worth up to $5.3 billion. The goal? To ...

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

Plenty folk have an asthma puffer but few seem to know how to use it. Adherium says its Hailie device is improving compliance ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using ...